Aelix Therapeutics

Parc Científic de Barcelona
Carrer Baldiri i Reixac 4-8
Barcelona

Tel: +34-93-403-1339

Website: http://www.aelixtherapeutics.com/

About Aelix Therapeutics

Aelix Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used as part of a cure/eradication strategy. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field. The company was incorporated in November 2015 and completed a €11.5M ($12.5M) Series A funding shortly thereafter.
YEAR FOUNDED:
November 2015
LEADERSHIP:
CEO: Dr. Cristina Quiles
Co-Founder and CSO: Dr Christian Brander
Acting CMO: Dr. Ian McGowan
Co-Founder and Executive Director: Jordi Naval

8 articles about Aelix Therapeutics

Clinical Catch-Up: March 8-12

3/15/2021

It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.
AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial

3/11/2021

AELIX Therapeutics S.L. (‘AELIX’), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces positive topline results in the AELIX-002 trial.
AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure

10/18/2018

AELIX Therapeutics will investigate the safety, immunogenicity, and efficacy of AELIX Therapeutics’ HTI vaccine and Gilead´s Toll-Like Receptor 7 agonist vesatolimod (GS-9620) in HIV-infected individuals
AELIX Therapeutics Appoints Dr. Thomas Hecht As Chairman Of The Board Of Directors

10/18/2017

Aelix Therapeutics announces the appointment of Dr. Thomas Hecht as chairman of its board of directors.
Aelix Therapeutics Enrolls First Patient In Company’s Initial Therapeutic HIV Vaccine Clinical Trial

9/5/2017
Aelix Therapeutics Appoints Dr. Ian Mcgowan As Chief Medical Officer

4/5/2017
Aelix Therapeutics Release: Company Appoints Industry Expert Philippe Monteyne As Independent Board Member

1/16/2017
Aelix Therapeutics Completes Series A Funding Of €11.5 Million ($12.7 Million) For Therapeutic HIV Vaccine

1/11/2016